
Scailyte is fundraising
Scailyte is fundraising
Scailyte is kicking off its new fundraising campaign!
We’re building on our strong commercial traction from 2024 and the hot business pipeline developed by our CBO, Tim Foley, following deep-dive discussions with biotech and pharma leaders at JPM Week. We are seeking like-minded investors who share our vision of a data-driven health future at single-cell resolution, where cutting-edge multi-omics data and AI drive prevention and precision healthcare.
Momentum: Precision medicine has entered the single-cell and multi-omics data era, with big pharma companies already embracing this groundbreaking technology. The next frontier is bringing it to clinical routine, and Scailyte is leading the charge.
Pioneer: As an ETH Zürich spin-off, Scailyte has established a robust biomarker and drug discovery platform, leveraging single-cell omics and proprietary AI algorithms. Over the past 7 years, we’ve developed multiple clinical biomarkers and built strategic partnerships with clinical-stage biotech and pharma companies.
Our Mission: Leverage single-cell multi-omics and AI to detect and treat diseases early & with high precision.
Our CEO, Peter Nestorov will be presenting Scailyte at:
- TechTour AI for Health – Bochum, Germany, Jan 23-24
- DeepTech Investor Summit – Zurich, Switzerland, Jan 27-28
Reach out to our CEO and join us in shaping the future of precision health.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...